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MINI-ABSTRACT 
 
A meta-analysis of patients with rectal cancer, assessing the prevalence of MRI detected 
extra-mural vascular invasion (mrEMVI), of metastases at presentation and after surgery in 
mrEMVI positive versus negative tumours. mrEMVI positive tumours were prevalent in 34% 
of reported studies and were over five more likely to present with metastases and almost four 
times more likely to develop metastases after surgery compared with mrEMVI negative 
tumours.  
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STRUCTURED-ABSTRACT 
Background: Pathologic extramural vascular invasion (EMVI) is an independent prognostic 
factor in rectal cancer but can also be identified on magnetic resonance imaging (mrEMVI). 
We perform a meta-analysis to determine the risk of metastatic disease at presentation and 
after surgery in mrEMVI positive patients compared with negative tumours.  
Methods: Electronic databases were searched from January 1980 to  
March 2016. Conventional meta-analytical techniques were used to provide a summative 
outcome. Quality assessment of the studies was performed.  
Results: Six articles reported on mrEMVI in 1262 patients. There were 403 patients in the 
mrEMVI positive group and 859 patients in the mrEMVI negative group. The combined 
prevalence of mrEMVI positive tumours was 0.346(Range=0.198-0.574). Patients with 
mrEMVI positive tumours presented more frequently with metastases compared to mrEMVI 
negative tumours [fixed effects model: OR=5.68, 95%CI(3.75,8.61), z=8.21, df=2, p<0.001]. 
Patients who were mrEMVI positive developed metastases more frequently during follow-up 
[random effects model:OR=3.91,95%CI(2.61,5.86),z=6.63,df=5,p<0.001].  
Conclusions: mrEMVI is prevalent in one third of patients with rectal cancer. mrEMVI is a 
poor prognostic factor as evidenced by the five fold increased rate of synchronous metastases 
and almost four fold ongoing risk of developing metastases in follow up after surgery. 
 
Key words: extramural vascular invasion, MRI, rectal cancer 
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INTRODUCTION: 
The link between histopathologic vascular invasion (EMVI) in specimens and metastatic 
disease was first reported in 1938 by Brown and Warren (Gibson et al., 2014). Talbot and 
colleagues subsequently showed that tumor spread into “thick-walled vessels” was evident in 
almost 52% of 703 rectal cancer specimens. Follow-up of their series showed a significantly 
worse 5-year survival rate and an almost four fold risk of developing liver metastases (40%) 
in patients with EMVI compared to EMVI negative tumours (14%) (Talbot et al.). The 
prevalence of EMVI varies greatly and is under-reported on histopathologic specimens 
(Messenger et al., 2012, Quasar Collaborative et al., 2007). The reasons for this may include 
lack of specific definitions and inconsistent analysis techniques despite efforts to improve 
this (Messenger et al., 2011, Kirsch et al., 2013).  
MRI is able to demonstrate normal veins within the mesorectum as distinctive low signal 
serpiginous structures and when disrupted or expanded by tumour signal this is strongly 
linked to the likelihood of pathologic EMVI being detected in the specimen. This led to the 
standardization of mrEMVI deifinitions in the preoperative assessment of rectal cancer as 
“serpiginous extension of tumour signal within a vascular structure – resulting in contiguous 
or discontinuous expansion of a vein by tumour signal” (supplementary figure 1) (Smith et 
al., 2008c, Brown et al., 2003, Shihab et al., 2011, Taylor et al., 2014a, Taylor et al., 2008, 
Nougaret et al., 2013, Chand et al., 2014b). By comparing pre and post treatment scans, MRI 
identifies the persistence of EMVI in a greater percentage of patients than histopathology 
(mrEMVI)(Chand et al., 2015a) and has a high sensitivity even when enhanced 
histopathologic techniques are used (Jhaveri et al., 2016). Several studies have reported the 
prevalence of mrEMVI and its correlation to the development of metastatic disease (Sohn et 
al., 2014, Chand et al., 2015a, Bugg et al., 2014, Smith et al., 2008c, Hunter et al., 2012, 
Seehaus et al., 2015, Kim et al., 2016).  Given the standardised, reproducible and 
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prognostically validated methods of describing tumour using MRI,  it is considered a 
standard for preoperative risk-stratification and treatment decision-making (Network, NICE, 
Glimelius et al., Ernst-Stecken et al., 2004, Brown et al., 2003, Chand et al., 2015b, 2006, 
Battersby et al., 2015, Yu et al., 2014, Taylor et al., 2014b, Taylor et al., 2011, Smith et al., 
2008a, Shihab et al., 2011). Despite this, patients presenting with the finding of mrEMVI are 
treated in different ways with a lack of consensus on the use of adjuvant therapy. In a recent 
survey, only 55% of surgeons and 57% of oncologists considered it when deciding on post-
operative treatment; this may lead to under-estimation of the risks of metastatic disease and 
the consequent under-treatment of an MRI identified high-risk group (Chand et al., 2014a). 
Identifying the true overall prevalence of mrEMVI and the risk of metastatic disease will help 
in establishing the need, or lack thereof, for further treatment strategies and would certainly 
aid in patient discussions regarding the potential advantages or disadvantages of adjuvant 
therapy. 
This meta-analyses aims to establish the true overall prevalence of rectal tumours with 
mrEMVI, its association with metastatic disease at the time of presentation and development 
of distant disease after surgery. 
METHODS 
Registration & protocol 
This meta-analysis was registered on the PROSPERO database a priori with an outline of the 
proposed hypotheses and analysis (Siddiqui et al.).  
Hypothesis 
Tumours that are mrEMVI positive demonstrate a higher incidence of synchronous and 
metachronous metastases compared with mrEMVI negative tumours. 
Searching and Selection 
All studies examining the outcomes in patients with rectal cancer and MRI-detected 
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extramural vascular invasion (EMVI) from January 1980 (first human publications regarding 
MRI) to July 2016 were identified. The MEDLINE, EMBASE and CINAHL databases 
available through the United Kingdom's National Health Service National Library of Health 
website, the Cochrane library and PubMed available online. Text words “rectal cancer”, 
“vascular invasion”, “extramural”, “tumour in vessels”, “medical imaging”, “magnetic 
resonance”, “MRI” were used in combination with the medical subject heading “rectal 
cancers”.  Irrelevant articles, reviews and meta-analyses evident from the titles and abstracts 
were excluded. Relevant articles referenced in these publications were obtained and the 
references of identified studies were searched to identify any further studies.  No language 
restriction was applied. A flow chart of the literature search according to PRISMA guidelines 
(Liberati et al., 2009) is shown in supplementary figure 2. 171 articles were screened for 
relevance. Of the 171 papers initially detected there were 55 duplicates leaving 116 records. 
Of these 116 records that were screened, most were pathology based and were excluded. 
Some of the studies were reviews and some studies captured by our search strategy were on 
unrelated subjects. On further scrutiny 6 studies comparing outcomes of rectal tumours with 
and without mrEMVI were found to have useful data for the summative outcome.  
Quality Assessment 
The methodological quality of the trials included for meta-analysis is explained 
comprehensively in Table 3. Assessment was performed by 2 authors independently 
(M.R.S.S. & J.B) (Rangel et al., 2003, Chalmers et al., 1981, Jadad et al., 1996). 
Data Extraction 
Each included article according to our meta-analysis criteria (Supplemenary table 1) was 
reviewed by two researchers.  This was performed independently and if any conflict arose 
resolution was through discussion prior to analysis. Only papers examining outcomes in 
rectal cancer with and without mrEMVI were included.  Where more specific data was 
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required the authors of manuscripts were contacted. Our main outcome measures were 
synchronous and metachronous metastases. For the purposes of this meta-analysis, 
synchronous metastases were defined as the presence of metastatic disease prior to surgical 
intervention and metachronous disease was defined as the occurrence of metastases after 
surgery during the follow-up period. 
Data Synthesis 
Statistical analyses were performed using Comprehensive Meta-Analysis 2006 for Windows 
XP (Borenstein M, 2005).  A value of p<0.05 was chosen as the significance level for 
outcome measures. Binary data (number of metastases) were summarized as risk ratios (OR) 
and combined using the Mantel-Haenszel method (Egger et al., 2006). Heterogeneity of the 
studies was assessed according to Q and I2. A random and fixed effects method was used. 
Studies were excluded on an individual basis to assess for influence on heterogeneity. In a 
sensitivity analysis, 1 was added to each cell frequency for trials in which no event occurred, 
according to the method recommended by Deeks et al (Deeks et al., 2001). Forest plots were 
used for the graphical display.  
RESULTS 
Six articles (Sohn et al., 2014, Chand et al., 2015a, Bugg et al., 2014, Smith et al., 2008c, 
Hunter et al., 2012, Seehaus et al., 2015) reporting on metastatic disease in patients with 
rectal cancer and extramural vascular invasion were retrieved from the electronic databases 
met the inclusion criteria (Supplemenary table 1). Two studies were from the same center but 
evaluated different time cohorts (Chand et al., 2015a, Smith et al., 2008c). One study 
included a combination of synchronous and metachronous metastases (predominately 
synchronous) and was included in the analyses for both outcome measures, exclusion of this 
study did not alter the significance for both synchronous or metachronous metastases (Sohn 
et al., 2014). For one study, the  mrEMVI status in a cohort of patients was obtained after 
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contacting the authors (Hunter et al., 2012). A further study evaluated persistent ymrEMVI 
status after preoperative chemoradiotherapy (Chand et al., 2015a). Characteristics of each 
article are given in Table 1 and 2. The methodological quality of the trials included for meta-
analysis is shown in Table 3 (Rangel et al., 2003, Chalmers et al., 1981, Jadad et al., 1996). 
Prevalence of MRI defined EMVI positive rectal tumours 
The combined prevalence of mrEMVI positive tumours from the six studies (Sohn et al., 
2014, Chand et al., 2015a, Bugg et al., 2014, Smith et al., 2008c, Hunter et al., 2012, Seehaus 
et al., 2015) was 0.346 (CI=0.237-0.474) and is graphically portrayed in figure 1. 
Synchronous metastases 
Three studies incorporating a total of 804 patients (Smith et al., 2008b, Sohn et al., 2014, 
Hunter et al., 2012) contributed towards a summative outcome. Seventy patients had 
metastases out of 212 patients with mrEMVI (33%). Fifty-two patients presented with 
metastases out of 592 patients without mrEMVI (9%).  
Patients with mrEMVI positive tumours presented more frequently with metastases at 
presentation compared to mrEMVI negative tumours [fixed effects model: OR=5.68,95% 
CI(3.75,8.61),z=8.21,p<0.001; figure 2].  There was no significant heterogeneity among trials 
(Q=1.85,df=2,p=0.40,I2=0) and the fixed effects model was used.  
In a sensitivity analysis one study was excluded (Sohn et al., 2014) due to clinical 
heterogeneity (inclusion of synchronous and metachronous metastases) although the 
heterogeneity was not reduced and the outcome remained significant [fixed effects model: 
OR=4.60, 95% CI (2.34,9.07), z=4.41, p<0.001]. Thus patients with mrEMVI were over four 
times more likely to present with metastases compared to patients without mrEMVI.  
Metachronous metastases 
Six studies incorporating 1262 patients (Sohn et al., 2014, Chand et al., 2015a, Bugg et al., 
2014, Smith et al., 2008c, Hunter et al., 2012, Stewart et al., 2007) contributed towards a 
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summative outcome. 159 out of 403 patients had metastases and were mrEMVI positive 
(39%). 125 out of 859 patients had metastases and were mrEMVI negative (15%).  
Patients who had mrEMVI positive tumours more often had metastases during follow-up 
compared with mrEMVI negative tumours [fixed effects model: OR=4.02, 95%CI 
(2.99,5.39), z=9.26, p<0.001; random effects model: OR=3.91, 95%CI (2.61,5.86), z=6.63, 
p<0.001; figure 3]. There was no significant heterogeneity among trials 
(Q=8.53,df=5,p=0.129,I2=41) and the fixed and random effects models were used.  
One study was excluded (Sohn et al., 2014) due to clinical heterogeneity (inclusion of 
synchronous and metachronous metastases) and heterogeneity was reduced 
(Q=4.35,df=5,p=0.36,I2=8) but the outcome remained significant [fixed effects model: 
OR=3.26, 95% CI (2.29,4.66), z=4.35, p<0.001]. Therefore patients with mrEMVI over three 
times more likely to develop metastases than mrEMVI negative tumours. 
DISCUSSION  
The present analysis has shown that mrEMVI indicates poorer disease free survival (DFS) 
(Chand et al., 2014b). Thus, identifying the burden of disease in the population and its almost 
4 fold increased risk of further metastatic disease may in future influence the use of 
neoadjuvant and adjuvant treatment strategies and certainly warrants future trial designs that 
take into account the presence of mrEMVI as a risk factor.  
Main findings 
This analysis of 804 patients has shown that those with mrEMVI are five times more likely to 
have metastases at presentation compared to those without. Analysis of 1262 with mrEMVI 
positive tumours are almost four times more likely to develop metastases on follow-up. The 
meta-analysis has also shown that MRI detected prevalence of EMVI in rectal cancer is 
34.6% (CI: 23.7-47.4%) and thus amounts to over a third of all rectal cancers. Although the 
link between pathologic EMVI and liver metastases is well established (Talbot et al., 1980), 
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its reporting by individual pathologists is highly variable with documented pathologic under-
reporting of pEMVI resulting in rates of only 9-21%  in published audits  (Kirsch et al., 
Messenger et al., Messenger et al., Betge et al., 2012, Bhangu et al., 2013, Courtney et al., 
2009, Gibson et al., 2014, Stewart et al., 2007). Furthermore pathologic EMVI status is only 
available after surgery thus limiting the ability to tailor preoperative therapy. Arguably, MRI 
assessment of EMVI can be justified as a gold standard as it has both a higher detection rate 
and represents an independent risk factor for recurrence. 
Importance and clinical implications 
mrEMVI positive tumours represent a large cohort (34.6%) within the rectal cancer 
population and carry a significantly high risk of metastatic disease. Its positive identification 
could lead to better surveillance of high risk patients  as well as future improvements in 
therapeutic strategies (Hunter et al., 2012, Slesser et al.). This analysis has quantified the 
metastatic risk at presentation and after surgery following analysis of more than 800 patients 
who were identified as mrEMVI positive thus enabling important prognostic information 
from the preoperative MRI assessment to be shared with patients.  This is relevant because 
the current TNM classification and treatment policies largely fail to account for this 
prognostic group(Bujko et al., 2010). Existing recommendations for patients with pEMVI are 
based on historical studies which were limited by the low prevalence and under-reporting of 
EMVI or misreporting vascular tumour deposits as “lymph nodes” (Ueno et al., 2007, Ueno 
et al., 2012) . Node negative tumours in such studies showed a far greater overall survival and 
disease free survival rates than those currently observed in mrEMVI positive node negative 
tumours (Quasar Collaborative et al., 2007). The potential benefit of adjuvant chemotherapy 
in this previously unidentified group consequently remains uncertain (Quasar Collaborative 
et al., 2007). The risk of metastatic disease associated with mrEMVI has implications for 
administration of long course chemoradiotherapy (LCRT) with additional preoperative 
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chemotherapy given either before or after LCRT and this is currently under investigation in a 
number of clinical trials (Nilsson et al., 2013, Slesser et al., 2015, Courtney et al.).   
Appraisal of evidence and heterogeneity 
The overall incidence of mrEMVI in the individual studies were similar except for two 
studies which showed a prevalence of 53% (Chand et al., 2015a) and 57% (Seehaus et al., 
2015). One of these studies evaluated a population limited to advanced rectal tumours 
undergoing preoperative chemoradiotherapy which accounts for the higher prevalence 
(Chand et al., 2015a). The other studies included both earlier and locally advanced stage 
tumours (Smith et al., 2008b, Sohn et al., 2014, Thomson et al., 2015). In this meta-analysis 
one study included only mrEMVI positive patients at baseline and compared patients who 
were persistently positive with EMVI that regressed. In this paper, those tumours that 
regressed to ymrEMVI negative had similar low rates of metastatic disease as those who are 
mrEMVI negative on baseline scans (Chand et al., 2015a). The link between mrEMVI in 
metastatic disease has been further highlighted by studies showing that about 90% of patients 
with hepatic metastases are EMVI positive (Slesser et al., 2015). One limitation of this 
analysis is that the cohorts may not be truly comparable due to tumour related factors 
however most of our results did not identify significant heterogeneity between studies for the 
outcomes of interest, suggesting the cohorts are comparable. In the results where there was 
significant heterogeneity (clinical or statistical), it sets the stage for further research to 
identify the reasons for variability and inconsistency between studies. This meta-analysis has 
more power than individual studies to identify a true difference that exists between two 
groups, especially for outcomes that require larger sample sizes. In addition, our meta-
analysis not only has more power to identify statistical difference, but also, increases the 
precision in estimating the size of the effects of difference between groups. 
Quality assessment & Limitations 
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Quality assessment of the studies (retrospective reviews of databases) included in this meta-
analysis is shown in table 3. It is too early to comment on publication bias.  
The individual articles in our studies showed clinical heterogeneity when examining 
metastatic disease after surgery and this may be due to differing follow-up times. One study 
included synchronous and metachronous metastases (Sohn et al., 2014) and when excluded 
from our analysis reduced the heterogeneity. Some studies (such as Smith et al) included in 
our meta-analysis had small sample sizes that resulted in wide confidence intervals and 
caution should be used when drawing conclusions.  Despite the lack of statistical 
heterogeneity, the clinical differences need to be borne in mind as well as the relatively small 
number of patients retrieved from the literature. The small numbers involved also has the 
potential for over-estimating the Odds Ratios of our overall outcome results and therefore 
although our results are strongly supportive of our conclusions caution should be maintained 
and further trials would certainly be warranted. One potential area is that of tumour related 
factors which may affect the results however all the pre-operative variables assessed were 
comparable in the studies and whilst contributing to heterogeneity and to some extent the 
overall odds ratios it is unlikely to affect the direction of the result. The MERCURY II study 
has also shown that nodal status did not predict for local or distant failure, in addition the 
mrEMVI positivity rate was greater than the CRM positive rate therefore making mrEMVI 
likely to be a more predictive factor (Battersby et al., 2015). Further studies should 
standardise follow up of cases to add further to the literature.  
Future studies 
Further prospective matched-cohort studies focusing on outcomes will help in risk 
stratification of mrEMVI positive tumours. The clear definitions of EMVI identified on MRI, 
and confirmed in this meta-analysis, means that this imaging modality should be adopted as 
the gold standard in assessment of this prognostic factor.  This analysis has shown that 
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mrEMVI is a likely precursor to metastatic disease and will be formally tested in a 
prospective study . With its greater detection of patients who are at high risk of developing 
metastatic disease than current methods, treatment with systemic chemotherapy may, in 
future, reduce the risk of recurrent disease. Further research into the biological processes of 
development of metastases and mrEMVI may be facilitated by study into release of tumour 
cells and DNA into the circulation (Talbot et al., 1981).  
CONCLUSION 
EMVI is a poor prognostic factor in rectal cancer. It is now readily identified on MRI as an 
independent prognostic factor with a significant prevalence in rectal tumour population.  This 
meta-analysis has shown that patients with mrEMVI positive tumours are over five times 
more likely to have synchronous metastases and over three times as likely to develop 
metastases after surgery. 
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Table Legends 
 
Table 1 – Outcome measures 
 
Table 2 – Characteristics of included studies 
 
Table 3 - Methodological qualities of comparative studies included  
 
Figure legends 
 
Figure 1 – The proportion of patients with rectal cancer who have extramural vascular 
invasion identified on MRI at the time of presentation 
 
Figure 2 – The proportion of patients with metastases at the time of presentation who have 
mrEMVI positive tumours versus mrEMVI negative tumours 
 
Figure 3 – The proportion of patients who develop metastases after surgery who had 
mrEMVI positive tumours before surgery versus mrEMVI negative tumours before surgery 
 
Supplementary Table 1 – Inclusion Criteria 
 
Supplementary Figure 1 – MRI features of EMVI 
 
Supplementary Figure 2 – Search Strategy 
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Table 1: Outcome measures 
 
 
 
 
 
ND = No Data; *data was combined with synchronous and metachronous (6 months post surgery), most were synchronous but unable to extract breakdown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients (n) 
        EMVI + 
        EMVI - 
 
Number with metachronous metastases  
        EMVI + 
        EMVI - 
 
Number of local recurrences 
        EMVI + 
        EMVI - 
 
Disease/Recurrence Free Survival (3yr) 
        EMVI + 
        EMVI - 
 
Number with synchronous metastases 
        EMVI + 
        EMVI - 
 
Site of  metachronous metastases 
        EMVI + (Lung/Liver/Multi/Other) 
        EMVI - (Lung/Liver/Multi/Other) 
 
Site of  synchronous metastases 
        EMVI + (Lung/Liver/Multi/Other) 
        EMVI - (Lung/Liver/Multi/Other) 
Smith et al 2008 Hunter et al 2012 Bugg et al 2014 Sohn et al 2014 Chand et al 2015 Seehaus et al 2015 
 
 
24 
97 
 
 
18 
41 
 
 
ND 
ND 
 
 
35% (sd=9.75) 
74.1% (sd=4.53) 
 
 
7 
4 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
 
90 
146 
 
 
35 
18 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
21 
11 
 
 
4/15/12/4 
1/6/11/0 
 
 
2/12/3/4 
4/4/2/1 
 
 
 
53 
149 
 
 
13 
10 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
 
98 
349 
 
 
42* 
37* 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
42* 
37* 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
 
99 
89 
 
 
36 
14 
 
 
5 
3 
 
 
42.7% (sd=12.95) 
79.2 (sd=4.6) 
 
 
ND 
ND 
 
 
5/4/4/23 
7/1/2/4 
 
 
ND 
ND 
 
 
 
39 
29 
 
 
15 
5 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
ND 
ND 
 
 
ND/15/ND/ND 
ND/5/ND/ND 
 
 
ND 
ND 
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Table 2: Characteristics of studies comparing patients with and without EMVI 
 
 
 
 
ND = No Data; M = Mix of cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Number of paients (n) 
 
Age of patients (range) 
 
Gender (m:f) 
 
 
Tumour (MRI) 
            T-stage 
 
           Node positive 
 
           CRM positive 
 
           Height 
 
 
 
 
 
Neoadjuvant/Adjuvant Therapy 
 
Follow up 
 
 
Smith et al 2008 Hunter et al 2012 Bugg et al 2014 Sohn et al 2014 Chand et al 2015 Seehaus et al 2015 
 
121 
 
ND 
 
77:65 
 
 
236 
 
64.5 (sd=13) 
 
161:69 (ND=6) 
 
202 
 
66 (32-84) 
 
123:79 
 
447 
 
61.0 (36.6-75.4) 
 
291:156 
 
188 
 
ND 
 
121:67 
 
68 
 
64.3 (sd=14) 
 
44:24 
 
 
T3 
 
ND 
 
ND 
 
ND 
 
 
 
 
Overall Stage 
III&IV: 89 
 
ND 
 
 
Low – 100 
Middle – 54 
High – 76 
ND - 6 
 
 
ND 
 
ND 
 
ND 
 
ND 
 
 
 
T3 
 
286 
 
75 
 
Below Peritoneal 
Reflection – 259 
Above Peritoneal 
Reflection - 61 
 
 
137 (Defined as >3c) 
 
123 
 
81 
 
Low – 69 
Middle – 62 
High - 57 
 
 
T3 
 
ND 
 
ND 
 
Low – 32 
Middle – 36 
High - 0 
 
+/+ (M) 
 
36 months 
 
+/- 
 
36 months 
 
Primary Surgery Only 
 
12 months 
 
Primary Surgery/+ (M) 
 
6 months 
 
+/+ 
 
36 months 
 
ND/ND 
 
12 months 
Study methodology 
           Country 
          
           Time period 
 
UK cohort – London 
 
2000-2004 
 
Canadian Cohort 
 
2004-2008 
 
UK cohort – E.Anglia 
 
2007-2012 
 
Korean cohort 
 
2011-2012 
 
UK cohort - London 
 
2006-2013 
 
South American Cohort 
 
2011-2012 
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Table 3.  Methodological qualities of comparative studies included  
(Adapted from the Scottish Intercollegiate Guidelines Network and Rangel et al 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Quality measures 
Smith et al 
2008 
Hunter et al 
2012 
Bugg et al 
2014 
Sohn et al 
2014 
Chand et al 
2015 
Seehaus et al 
2015 
Inclusion Criteria 1 1 1 1 1 0.5 
Exclusion Criteria 1 1 1 1 1 1 
Can the number of participating 
centers be determined 
1 1 1 1 1 1 
Can the number of radiologists 
who participated be determined 
0 0 0 0 0 1 
Can the reader determine where the authors are on the 
learning curve for the reported procedure 
0 0 0 0 0 1 
Are diagnostic criteria clearly 
stated for clinical outcomes if required 
1 1 1 0 1 1 
Is there any way that they have tried to standardize the 
radiological interpretation 
1 1 1 0 1 1 
Do authors address whether 
there is any missing data 
1 1 1 1 1 1 
Were patients in each group 
treated along similar timelines 
1 1 1 1 1 1 
Outcomes clearly defined? 1 1 1 0 1 1 
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Figure 1 – The proportion of patients with rectal cancer who have extramural vascular 
invasion identified on MRI at the time of presentation 
 
 
 
  
Figure'2'–'Incidence'of'extramural'vascular'invasion'identi7ied'on'MRI'
'
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Figure 2 – The proportion of patients with metastases at the time of presentation who have 
mrEMVI positive tumours versus mrEMVI negative tumours 
 
 
 
 
 
 
  
Figure'3'–'Synchronous'metastases'in'EMVI'positive'and'negative'tumours'
'
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Figure 3 – The proportion of patients who develop metastases after surgery who had 
mrEMVI positive tumours before surgery versus mrEMVI negative tumours before surgery 
 
 
 
 
 
 
 
 
 
 
 
Figure'4'–'Metachronous'metastases'in'EMVI'positive'and'n gativ 'tumours'
'
